Joshua E.Verified buyer
Jun 20, 2026
★★★★★
Absolutely pure and incredibly fast shipping
I’m so glad I tried this. After problems with post surgery and even PRP injections, this is what finally helped me!
Research summary
BPC-157 — clinical & mechanistic profile
BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protective protein. As of 2026, only 3 published human studies exist (all pilot-scale with <30 subjects), but 500+ preclinical studies show tissue healing effects. A 2025 IV safety study (up to 20mg) in healthy adults showed no adverse events across cardiac, hepatic, and renal biomarkers.
Research status
preclinical
Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular weight
1419.53 Da
Molecular formula
C62H98N16O22
Studied applications
- •Peptide research pathways: studied in tendon, ligament, and muscle injury models with histological and biomechanical endpoints
- •Vascular and NO signaling: investigated for effects on microcirculation and endothelial behavior in stress and injury contexts
- •Protective signaling: examined in gastrointestinal, neural, and systemic injury models across multiple organ systems
- •Fibroblast activity: associated with extracellular matrix remodeling and cell migration in connective tissue models
- •Gastrointestinal integrity: studied in gastric ulcer, IBD, and intestinal anastomosis models for mucosal protection
- •Central nervous system: explored in nerve injury and neurodegenerative disease models in rodents
Mechanisms of action
- •VEGF and angiogenesis: upregulates VEGF expression in vivo, activates VEGFR2 receptors on endothelial cells, triggers Akt-eNOS pathway phosphorylation
- •Nitric oxide modulation: enhances endothelial NOS (eNOS) activity via Src-Cav-1-eNOS pathways, influences NO synthase activity and vascular tone
- •Cell migration signaling: modulates FAK (focal adhesion kinase) and paxillin pathways affecting cell migration and adhesion
- •Somatotropic receptor: boosts GHR expression in tendon fibroblasts, enhancing collagen synthesis in rodent studies
- •ERK1/2 phosphorylation: activates downstream targets (c-Fos, c-Jun, Egr-1) promoting cell growth and migration
- •Cytoprotective action: functions as membrane stabilizer and free radical scavenger in controlled studies
Research constraints & safety notes
- •No completed human clinical trials establishing safety or efficacy - majority of evidence is preclinical (in vitro and animal models)
- •Preclinical findings do not establish clinical efficacy in humans and should be interpreted within experimental model limitations
- •Research originates predominantly from a limited number of research groups, with variable independent replication
- •Not approved by FDA, EMA, or any regulatory agency for therapeutic, medical, or supplemental use in humans
- •Classified as Category 2 bulk drug substance by FDA (2023) - cannot be compounded by commercial pharmaceutical companies
Peer-reviewed references
- Sikiric P, et al. — BPC 157: A Review of its Molecular Mechanisms (2019)PMID: 30915550View
- Chang CH, et al. — GH receptor expression in tendon fibroblasts (2011)PMID: 21030672View
- Vukojevic J, et al. — NO system interaction in vascular stress models (2011)PMID: 21842328View
- Sikiric P, et al. — Skin wounds, colon anastomoses, angiogenesis (1997)PMID: 9403790View
- Sikiric P, et al. — Multi-species preclinical safety evaluation (2020)PMID: 32334036View
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.
Related products